Molecular basis of hypertension side effects induced by sunitinib.
about
Hematopoietic stem cell transplantation and acute kidney injury in children: A comprehensive review.Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.Hypertension in cancer patients.Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors.Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertensionCardio-oncology Part I: chemotherapy and cardiovascular toxicity.Acute acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib.Life-threatening acute acalculous cholecystitis in a patient with renal cell carcinoma treated by sunitinib: a case report.Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.Systemic therapies for malignant pheochromocytoma and paraganglioma can exacerbate hypertension.Diagnosis, Treatment, and Prevention of Cardiovascular Toxicity Related to Anti-Cancer Treatment in Clinical Practice: An Opinion Paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiography.Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer.Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014-2017)
P2860
Q30234519-E04BE3C4-261C-41DD-85BC-1C9BE335515DQ35002540-BB915017-E1AF-45B5-8DDC-25310BA302D0Q35039529-24544088-55AA-4A84-82DC-D944839DD276Q36106439-B872D411-BE62-49B4-BEBF-85B3C6EB55B1Q36678295-11E11A90-4622-41D9-A734-D6479CBA03FFQ38406251-AB166CE9-985A-4CF8-99C0-A30DEDC13767Q39576475-6C767F4F-2DD3-4B06-A543-6683C12262B7Q42576779-8B044960-7802-4E3E-9347-353F74F9E1F8Q44096551-8F380C31-F189-4C19-B4B2-D6B552F1B4F7Q45900034-6E037240-4156-4D8F-BF3E-5396283A57CEQ53075042-33439A98-21D4-44F7-8582-EC5494F99B49Q55037961-3DFB702C-629D-4973-A35B-CF5902F0E699Q57652261-77A0FB5F-47E3-461B-9182-24E0D3339E1E
P2860
Molecular basis of hypertension side effects induced by sunitinib.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Molecular basis of hypertension side effects induced by sunitinib.
@ast
Molecular basis of hypertension side effects induced by sunitinib.
@en
Molecular basis of hypertension side effects induced by sunitinib.
@nl
type
label
Molecular basis of hypertension side effects induced by sunitinib.
@ast
Molecular basis of hypertension side effects induced by sunitinib.
@en
Molecular basis of hypertension side effects induced by sunitinib.
@nl
prefLabel
Molecular basis of hypertension side effects induced by sunitinib.
@ast
Molecular basis of hypertension side effects induced by sunitinib.
@en
Molecular basis of hypertension side effects induced by sunitinib.
@nl
P2093
P1433
P1476
Molecular basis of hypertension side effects induced by sunitinib.
@en
P2093
Begoña Campos-Balea
Francisco J Afonso-Afonso
Guadalupe Aparicio-Gallego
Jose L Fírvida-Pérez
Luis León-Mateos
Luis M Antón-Aparicio
Manuel Ramos-Vázquez
Martín Lázaro-Quintela
Ovidio Fernández-Calvo
Sergio Vázquez-Estévez
P356
10.1097/CAD.0B013E3283403806
P577
2011-01-01T00:00:00Z